Trial
NCT05074433
A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Regeneron Pharmaceuticals
Collaborators
—
Condition
Immunocompromised
Intervention
casirivimab+imdevimab
Why stopped
Emerging SARS-CoV2 variants impacting susceptibility to study drug
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-20